FLAG-liposomal Doxorubicin (Myocet) Regimen for Refractory or Relapsed Acute Leukemia Pediatric Patients

Journal of Pediatric Hematology/Oncology, 04/25/2012

Fludarabine with cytarabine and granulocyte colony–stimulating factor (FLAG) and nonpegylated liposomal doxorubicin (Myocet) proved to be safe in terms of acute cardiac toxicity although particular care must be taken to reduce infectious complications due to severe myelosuppression. The promising results shown in study need to be confirmed by larger and possibly randomized trials.

Print Article Summary Cat 2 CME Report